Three Reasons Why Decentralized Trial Models Using Mobile Research Nurses Yield Greater Financial Returns: New Studies Estimate DCTs Deliver More Than a Five-Fold ROI Due to Reductions in Clinical Phase Cycle Times, Decreases in Screen Failure Rates and Fewer Substantial Protocol Amendments

Published on: 

Sponsored Content

Decentralized trials (DCTs) have grown in acceptance since the COVID-19 pandemic when mobile research nurses were asked to step in to save hundreds of site-based clinical trials at risk of being postponed or cancelled because of mandated lockdowns. But despite their proven effectiveness, DCTs are still often an afterthought or an add-on option to site-based trials due to cost concerns The perception has been that deploying mobile research nurses to visit patients at their own homes would be more expensive than site-based trials. However, a recent study by the Tufts Center for the Study of Drug Development (Tufts) shows that not only are DCTs more patient-centric, but they also provide comparatively high returns on investments for sponsors.